摘要
血管生成是从原有血管中形成新的毛细血管的过程。血管生成参与了正常的生理过程,在肿瘤的浸润和转移中起着重要的作用。血管内皮生长因子(VEGF)在血管生成中起着关键的作用。血管内皮生长因子(VEGF)是血管内皮细胞的有丝分裂原并促进其增殖。通过抑制血管内皮生长因子的生物活性,并与中和血管内皮生长因子的抗体和信号抑制剂的信号通路级联,可能会对生长和转移进行负调节。抗血管生成疗法比化疗毒性小。血管生成是一个多步骤和多因素的过程,因此,可以不同的水平上阻止肿瘤的生成和转移。本文中作者提出了血管生成抑制剂新的合成方法,并总结了在体外实验在某些情况下的状态试验结果。
关键词: 血管生成,生物活性,肿瘤治疗,血管生成抑制剂,合成。
Current Medicinal Chemistry
Title:Inhibitors of Angiogenesis in Cancer Therapy – Synthesis and Biological Activity
Volume: 22 Issue: 33
Author(s): Monika Gensicka, Agnieszka Glowacka, Krystyna Dzierzbicka and Grzegorz Cholewinski
Affiliation:
关键词: 血管生成,生物活性,肿瘤治疗,血管生成抑制剂,合成。
摘要: Angiogenesis is the process of formation of new capillaries from preexisting blood vessels. Angiogenesis is involved in normal physiological processes, and plays an important role in tumor invasion and development of metastases. Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis. VEGF is a mitogen for vascular endothelial cells and stimulates their proliferation. By inhibiting the biological activity of VEGF, and then signal cascades with neutralizing VEGF antibodies and signal inhibitors, may negatively regulate the growth and metastasis. Anti-angiogenesis therapy is less toxic than chemotherapy. Angiogenesis is a multistep and multifactorial process, and therefore, can be blocked at different levels. In this review article, the authors present the synthesis of novel inhibitors of angiogenesis, together with the results of biological tests in vitro, and in some cases, state trials.
Export Options
About this article
Cite this article as:
Monika Gensicka, Agnieszka Glowacka, Krystyna Dzierzbicka and Grzegorz Cholewinski , Inhibitors of Angiogenesis in Cancer Therapy – Synthesis and Biological Activity, Current Medicinal Chemistry 2015; 22 (33) . https://dx.doi.org/10.2174/0929867322666150904111442
DOI https://dx.doi.org/10.2174/0929867322666150904111442 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
Anti-Cancer Agents in Medicinal Chemistry A Review on the Effects of Testosterone Supplementation in Hypogonadal Men with Cognitive Impairment
Current Drug Targets Trisodium Citrate Dihydrate-Catalyzed One-Pot Three-component Synthesis of Biologically Relevant Diversely Substituted 2-Amino-3-Cyano-4-(3- Indolyl)-4H-Chromenes under Eco-Friendly Conditions
Current Green Chemistry Regulation of Transcription Factors by Heterotrimeric G Proteins
Current Molecular Pharmacology Red and NIR Light-Responsive Polymeric Nanocarriers for On-Demand Drug Delivery
Current Medicinal Chemistry Genotoxicity of Nanocarriers
Current Drug Metabolism Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
Anti-Cancer Agents in Medicinal Chemistry Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design New Developments and Prospective Applications for β (1,3) Glucans
Recent Patents on Biotechnology Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells
Current Cancer Drug Targets Inhibition of PCAF by Anacardic Acid Derivative Leads to Apoptosis and Breaks Resistance to DNA Damage in BCR-ABL-expressing Cells
Anti-Cancer Agents in Medicinal Chemistry Use of Topiceuticals (Topically Applied, Peripherally Acting Drugs) in the Treatment of Chronic Pain
Current Drug Therapy Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) HIV Vaccination, is Breakthrough Underway?
Reviews on Recent Clinical Trials Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase C Modulates Aurora-kinase Inhibition Induced by CCT129202 in HMC-1560,816 Cell Line
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Calcium and Zinc DTPA Administration for Internal Contamination with Plutonium-238 and Americium-241
Current Pharmaceutical Biotechnology Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry